📰 Serial Studies News
Serial Studies News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Serial Studies. Real-time updates on events, politics, business and more.
March 30, 2023
/PRNewswire/ -- Exai Bio today announced a collaboration agreement with Quantum Leap Healthcare Collaborative™ (QLHC) to broaden the use of Exais novel,...
January 4, 2023
/PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the cyproheptadine arm of the study has been...
August 8, 2022
/PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announces that the cyclosporine arm of the study has been...
March 31, 2022
SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC) announced in collaboration with NRx Pharmaceuticals, In...
January 10, 2022
/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the Pulmozyme® (dornase alfa) arm of the...
December 3, 2021
/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...
December 3, 2021
/PRNewswire/ -- Today Quantum Leap Healthcare Collaborative (QLHC), sponsor of the I-SPY COVID Trial, announced that the IC14 arm of the trial has been...
December 3, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
June 18, 2021
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.